Cargando…
2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041304/ https://www.ncbi.nlm.nih.gov/pubmed/35496298 http://dx.doi.org/10.3389/fphar.2022.899633 |
_version_ | 1784694517700493312 |
---|---|
author | Huang, Zoufang Chavda, Vivek P. Vora, Lalitkumar K. Gajjar, Normi Apostolopoulos, Vasso Shah, Nirav Chen, Zhe-Sheng |
author_facet | Huang, Zoufang Chavda, Vivek P. Vora, Lalitkumar K. Gajjar, Normi Apostolopoulos, Vasso Shah, Nirav Chen, Zhe-Sheng |
author_sort | Huang, Zoufang |
collection | PubMed |
description | Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment. |
format | Online Article Text |
id | pubmed-9041304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90413042022-04-27 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update Huang, Zoufang Chavda, Vivek P. Vora, Lalitkumar K. Gajjar, Normi Apostolopoulos, Vasso Shah, Nirav Chen, Zhe-Sheng Front Pharmacol Pharmacology Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9041304/ /pubmed/35496298 http://dx.doi.org/10.3389/fphar.2022.899633 Text en Copyright © 2022 Huang, Chavda, Vora, Gajjar, Apostolopoulos, Shah and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Huang, Zoufang Chavda, Vivek P. Vora, Lalitkumar K. Gajjar, Normi Apostolopoulos, Vasso Shah, Nirav Chen, Zhe-Sheng 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update |
title | 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update |
title_full | 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update |
title_fullStr | 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update |
title_full_unstemmed | 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update |
title_short | 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update |
title_sort | 2-deoxy-d-glucose and its derivatives for the covid-19 treatment: an update |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041304/ https://www.ncbi.nlm.nih.gov/pubmed/35496298 http://dx.doi.org/10.3389/fphar.2022.899633 |
work_keys_str_mv | AT huangzoufang 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate AT chavdavivekp 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate AT voralalitkumark 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate AT gajjarnormi 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate AT apostolopoulosvasso 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate AT shahnirav 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate AT chenzhesheng 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate |